Symbols / GRI $2.37 -0.42% GRI Bio, Inc.
GRI Chart
About
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 3.42M |
| Enterprise Value | -4.72M | Income | -11.96M | Sales | — |
| Book/sh | 12.07 | Cash/sh | 5.70 | Dividend Yield | — |
| Payout | 0.00% | Employees | 3 | IPO | — |
| P/E | — | Forward P/E | -0.30 | PEG | — |
| P/S | — | P/B | 0.20 | P/C | — |
| EV/EBITDA | 0.39 | EV/Sales | — | Quick Ratio | 3.11 |
| Current Ratio | 3.25 | Debt/Eq | 1.18 | LT Debt/Eq | — |
| EPS (ttm) | -121.80 | EPS next Y | -8.03 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-01-30 07:00 | ROA | -103.93% |
| ROE | -238.17% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 1.45M |
| Shs Float | 1.45M | Short Float | 7.31% | Short Ratio | 1.95 |
| Short Interest | — | 52W High | 80.36 | 52W Low | 2.10 |
| Beta | -1.24 | Avg Volume | 361.79K | Volume | 7.21K |
| Target Price | $160.00 | Recom | None | Prev Close | $2.38 |
| Price | $2.37 | Change | -0.42% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$160.00
Mean price target
2. Current target
$2.41
Latest analyst target
3. DCF / Fair value
$-68.12
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.41
Low
$40.00
High
$280.00
Mean
$160.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-11 | main | Ascendiant Capital | Buy → Buy | $40 |
| 2025-12-08 | main | Ascendiant Capital | Buy → Buy | $36 |
| 2025-09-22 | main | Ascendiant Capital | Buy → Buy | $35 |
| 2025-06-11 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-05-27 | main | Ascendiant Capital | Buy → Buy | $34 |
| 2025-04-14 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-12-09 | init | HC Wainwright & Co. | — → Buy | $10 |
| 2024-12-05 | main | Ascendiant Capital | Buy → Buy | $13 |
News
RSS: Latest GRI news- If You Invested $1,000 in GRI Bio (GRI) - Stock Titan Mon, 23 Mar 2026 02
- Citigroup Issues Pessimistic Forecast for Grainger (LON:GRI) Stock Price - MarketBeat hu, 02 Apr 2026 20
- SAN GRI GL USD-A-AC (27916388.IR) Stock Forum & Discussion - Yahoo! Finance Canada Wed, 01 Apr 2026 19
- GRI Bio stock falls after announcing 1-for-28 reverse split - Investing.com Wed, 21 Jan 2026 08
- GRI Bio Inc. (GRI) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade Fri, 03 Apr 2026 00
- GRI Bio Announces Reverse Stock Split - GlobeNewswire Wed, 21 Jan 2026 08
- GRI Bio Reports Positive Study Results For Chronic Lung Disease, But Stock Slumps 20% — What Happened? - Stocktwits Wed, 28 Jan 2026 17
- GRI touts IPF safety edge, lung function gains amid cash crunch - Fierce Biotech hu, 11 Dec 2025 08
- GRI Bio Shareholders Authorize Reverse Stock Split Plan - TipRanks hu, 15 Jan 2026 08
- GRI Bio Eyes Topline Data For IPF Drug GRI-0621 Following Encouraging Interim Results - RTTNews hu, 18 Sep 2025 07
- Biotech GRI Bio extends cash runway after positive lung fibrosis trial data - Stock Titan Wed, 04 Feb 2026 08
- GRI Bio closes $8 million public offering of common stock and warrants - Investing.com Fri, 12 Dec 2025 08
- GRI Bio Announces Pricing of $8,000,000 Million Public Offering - finance.yahoo.com hu, 11 Dec 2025 08
- GRI Bio (NASDAQ: GRI) plans 1-for-28 reverse stock split in January - Stock Titan Wed, 21 Jan 2026 08
- GRI Bio stock rises on positive Phase 2a immune data for IPF treatment - Investing.com hu, 08 Jan 2026 08
Insider Transactions
No recent insider transactions.
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
11.98
+45.44%
|
8.23
-27.68%
|
11.39
+408.58%
|
2.24
|
| Research And Development |
|
6.82
+80.97%
|
3.77
+16.58%
|
3.23
+1235.54%
|
0.24
|
| Selling General And Administration |
|
5.16
+15.47%
|
4.47
-45.22%
|
8.15
+308.36%
|
2.00
|
| General And Administrative Expense |
|
5.16
+15.47%
|
4.47
-45.22%
|
8.15
+308.36%
|
2.00
|
| Other Gand A |
|
5.16
+15.47%
|
4.47
-45.22%
|
8.15
+308.36%
|
2.00
|
| Total Expenses |
|
11.98
+45.44%
|
8.23
-27.68%
|
11.39
+408.58%
|
2.24
|
| Operating Income |
|
-11.98
-45.44%
|
-8.23
+27.68%
|
-11.39
-408.58%
|
-2.24
|
| Total Operating Income As Reported |
|
-11.98
-45.44%
|
-8.23
+27.68%
|
-11.39
-408.58%
|
-2.24
|
| EBITDA |
|
-11.97
-45.46%
|
-8.23
+24.84%
|
-10.95
-327.61%
|
-2.56
|
| Normalized EBITDA |
|
-11.97
-45.46%
|
-8.23
+24.84%
|
-10.95
-389.76%
|
-2.24
|
| Reconciled Depreciation |
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
+33.33%
|
0.00
|
| EBIT |
|
-11.98
-45.44%
|
-8.23
+24.83%
|
-10.96
-327.26%
|
-2.56
|
| Total Unusual Items |
|
—
|
—
|
0.18
+156.00%
|
-0.33
|
| Total Unusual Items Excluding Goodwill |
|
—
|
—
|
0.18
+156.00%
|
-0.33
|
| Special Income Charges |
|
—
|
—
|
0.00
+100.00%
|
-0.33
|
| Other Special Charges |
|
—
|
—
|
—
|
0.33
|
| Net Income |
|
-11.96
-45.68%
|
-8.21
+37.05%
|
-13.04
-305.25%
|
-3.22
|
| Pretax Income |
|
-11.96
-45.68%
|
-8.21
+37.05%
|
-13.04
-305.25%
|
-3.22
|
| Net Non Operating Interest Income Expense |
|
0.02
-16.00%
|
0.03
+101.20%
|
-2.08
-218.84%
|
-0.65
|
| Interest Expense Non Operating |
|
—
|
—
|
2.08
+218.84%
|
0.65
|
| Net Interest Income |
|
0.02
-16.00%
|
0.03
+101.20%
|
-2.08
-218.84%
|
-0.65
|
| Interest Expense |
|
—
|
—
|
2.08
+218.84%
|
0.65
|
| Interest Income Non Operating |
|
0.02
-16.00%
|
0.03
|
—
|
—
|
| Interest Income |
|
0.02
-16.00%
|
0.03
|
—
|
—
|
| Other Income Expense |
|
—
|
0.00
-99.31%
|
0.43
+232.92%
|
-0.33
|
| Other Non Operating Income Expenses |
|
—
|
0.00
-99.31%
|
0.43
|
—
|
| Gain On Sale Of Security |
|
—
|
—
|
0.18
|
—
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-11.96
-45.68%
|
-8.21
+37.05%
|
-13.04
-305.25%
|
-3.22
|
| Net Income From Continuing Operation Net Minority Interest |
|
-11.96
-45.68%
|
-8.21
+37.05%
|
-13.04
-305.25%
|
-3.22
|
| Net Income From Continuing And Discontinued Operation |
|
-11.96
-45.68%
|
-8.21
+37.05%
|
-13.04
-305.25%
|
-3.22
|
| Net Income Continuous Operations |
|
-11.96
-45.68%
|
-8.21
+37.05%
|
-13.04
-305.25%
|
-3.22
|
| Normalized Income |
|
-11.96
-45.68%
|
-8.21
+37.05%
|
-13.04
-350.80%
|
-2.89
|
| Net Income Common Stockholders |
|
-11.96
-18.17%
|
-10.12
+22.39%
|
-13.04
-305.25%
|
-3.22
|
| Otherunder Preferred Stock Dividend |
|
0.00
-100.00%
|
1.91
|
—
|
—
|
| Diluted EPS |
|
-121.80
+92.12%
|
-1,545.55
+98.77%
|
-125,355.77
-164.97%
|
-47,308.82
|
| Basic EPS |
|
-121.80
+92.12%
|
-1,545.55
+98.77%
|
-125,355.77
-164.97%
|
-47,308.82
|
| Basic Average Shares |
|
0.10
+1399.56%
|
0.01
+6194.23%
|
0.00
+52.94%
|
0.00
|
| Diluted Average Shares |
|
0.10
+1399.56%
|
0.01
+6194.23%
|
0.00
+52.94%
|
0.00
|
| Diluted NI Availto Com Stockholders |
|
-11.96
-18.17%
|
-10.12
+22.39%
|
-13.04
-305.25%
|
-3.22
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
8.67
+51.00%
|
5.74
+94.15%
|
2.96
+671.80%
|
0.38
|
| Current Assets |
|
8.59
+53.02%
|
5.62
+91.38%
|
2.93
+840.38%
|
0.31
|
| Cash Cash Equivalents And Short Term Investments |
|
8.23
+63.66%
|
5.03
+178.10%
|
1.81
+19988.89%
|
0.01
|
| Cash And Cash Equivalents |
|
8.23
+63.66%
|
5.03
+178.10%
|
1.81
+19988.89%
|
0.01
|
| Cash Financial |
|
8.23
+63.66%
|
5.03
+178.10%
|
1.81
+19988.89%
|
0.01
|
| Other Current Assets |
|
0.36
-38.16%
|
0.59
-47.87%
|
1.13
+271.62%
|
0.30
|
| Total Non Current Assets |
|
0.07
-40.32%
|
0.12
+463.64%
|
0.02
-69.01%
|
0.07
|
| Net PPE |
|
0.07
-40.32%
|
0.12
+463.64%
|
0.02
-69.01%
|
0.07
|
| Gross PPE |
|
0.11
-29.87%
|
0.15
+220.83%
|
0.05
-48.39%
|
0.09
|
| Accumulated Depreciation |
|
-0.03
-13.33%
|
-0.03
-15.38%
|
-0.03
-18.18%
|
-0.02
|
| Machinery Furniture Equipment |
|
0.04
+8.82%
|
0.03
+0.00%
|
0.03
+30.77%
|
0.03
|
| Other Properties |
|
0.07
-40.83%
|
0.12
+757.14%
|
0.01
-79.10%
|
0.07
|
| Non Current Prepaid Assets |
|
—
|
—
|
—
|
0.00
|
| Total Liabilities Net Minority Interest |
|
2.66
+55.71%
|
1.71
-36.71%
|
2.70
+34.31%
|
2.01
|
| Current Liabilities |
|
2.64
+61.55%
|
1.64
-39.34%
|
2.70
+35.26%
|
1.99
|
| Payables And Accrued Expenses |
|
2.59
+62.91%
|
1.59
-40.75%
|
2.68
+101.50%
|
1.33
|
| Payables |
|
1.84
+104.79%
|
0.90
-36.38%
|
1.41
+8.96%
|
1.29
|
| Accounts Payable |
|
1.84
+104.79%
|
0.90
-36.38%
|
1.41
+8.96%
|
1.29
|
| Current Accrued Expenses |
|
0.75
+8.54%
|
0.69
-45.59%
|
1.27
+3427.78%
|
0.04
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
—
|
—
|
—
|
0.03
|
| Current Debt And Capital Lease Obligation |
|
0.06
+16.67%
|
0.05
+242.86%
|
0.01
-97.88%
|
0.66
|
| Current Debt |
|
—
|
—
|
—
|
0.60
|
| Other Current Borrowings |
|
—
|
—
|
—
|
—
|
| Current Capital Lease Obligation |
|
0.06
+16.67%
|
0.05
+242.86%
|
0.01
-75.44%
|
0.06
|
| Current Deferred Liabilities |
|
—
|
—
|
0.00
-100.00%
|
0.01
|
| Other Current Liabilities |
|
—
|
—
|
0.00
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
0.01
-78.87%
|
0.07
|
0.00
-100.00%
|
0.01
|
| Long Term Debt And Capital Lease Obligation |
|
0.01
-78.87%
|
0.07
|
0.00
-100.00%
|
0.01
|
| Long Term Capital Lease Obligation |
|
0.01
-78.87%
|
0.07
|
0.00
-100.00%
|
0.01
|
| Stockholders Equity |
|
6.01
+49.01%
|
4.03
+1456.76%
|
0.26
+115.94%
|
-1.62
|
| Common Stock Equity |
|
6.01
+49.01%
|
4.03
+1456.76%
|
0.26
+115.94%
|
-1.62
|
| Capital Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Common Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
0.50
+2551.95%
|
0.02
+17945.19%
|
0.00
+52.94%
|
0.00
|
| Ordinary Shares Number |
|
0.50
+2551.95%
|
0.02
+17945.19%
|
0.00
+52.94%
|
0.00
|
| Additional Paid In Capital |
|
57.70
+31.83%
|
43.77
+37.68%
|
31.79
+88.44%
|
16.87
|
| Retained Earnings |
|
-51.70
-30.09%
|
-39.74
-26.03%
|
-31.53
-70.49%
|
-18.50
|
| Total Equity Gross Minority Interest |
|
6.01
+49.01%
|
4.03
+1456.76%
|
0.26
+115.94%
|
-1.62
|
| Total Capitalization |
|
6.01
+49.01%
|
4.03
+1456.76%
|
0.26
+115.94%
|
-1.62
|
| Working Capital |
|
5.95
+49.51%
|
3.98
+1578.90%
|
0.24
+114.09%
|
-1.68
|
| Invested Capital |
|
6.01
+49.01%
|
4.03
+1456.76%
|
0.26
+125.32%
|
-1.02
|
| Total Debt |
|
0.07
-40.34%
|
0.12
+750.00%
|
0.01
-97.92%
|
0.67
|
| Net Debt |
|
—
|
—
|
—
|
0.59
|
| Capital Lease Obligations |
|
0.07
-40.34%
|
0.12
+750.00%
|
0.01
-80.28%
|
0.07
|
| Net Tangible Assets |
|
6.01
+49.01%
|
4.03
+1456.76%
|
0.26
+115.94%
|
-1.62
|
| Tangible Book Value |
|
6.01
+49.01%
|
4.03
+1456.76%
|
0.26
+115.94%
|
-1.62
|
| Current Notes Payable |
|
—
|
—
|
0.00
-100.00%
|
0.60
|
| Interest Payable |
|
—
|
—
|
—
|
0.00
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-10.19
-18.29%
|
-8.61
+4.22%
|
-8.99
-728.57%
|
-1.08
|
| Cash Flow From Continuing Operating Activities |
|
-10.19
-18.29%
|
-8.61
+4.22%
|
-8.99
-728.57%
|
-1.08
|
| Net Income From Continuing Operations |
|
-11.96
-45.68%
|
-8.21
+37.05%
|
-13.04
-305.25%
|
-3.22
|
| Depreciation Amortization Depletion |
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
+33.33%
|
0.00
|
| Depreciation |
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
+33.33%
|
0.00
|
| Depreciation And Amortization |
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
+33.33%
|
0.00
|
| Other Non Cash Items |
|
0.05
+145.71%
|
-0.10
-104.87%
|
2.16
+894.01%
|
0.22
|
| Stock Based Compensation |
|
0.79
+435.81%
|
0.15
-61.86%
|
0.39
+1452.00%
|
0.03
|
| Asset Impairment Charge |
|
—
|
—
|
0.05
+12.77%
|
0.05
|
| Operating Gains Losses |
|
—
|
-0.00
+98.35%
|
-0.18
-156.00%
|
0.33
|
| Gain Loss On Investment Securities |
|
—
|
-0.00
+98.35%
|
-0.18
|
—
|
| Change In Working Capital |
|
0.93
+306.47%
|
-0.45
-126.67%
|
1.68
+10.89%
|
1.51
|
| Change In Prepaid Assets |
|
0.25
-19.81%
|
0.31
+157.22%
|
-0.55
-1462.86%
|
-0.04
|
| Change In Payables And Accrued Expense |
|
0.72
+183.37%
|
-0.87
-137.92%
|
2.28
+43.38%
|
1.59
|
| Change In Accrued Expense |
|
0.06
+112.32%
|
-0.48
-483.20%
|
0.12
-82.04%
|
0.70
|
| Change In Payable |
|
0.66
+271.32%
|
-0.39
-117.92%
|
2.16
+140.69%
|
0.90
|
| Change In Account Payable |
|
0.66
+271.32%
|
-0.39
-117.92%
|
2.16
+140.69%
|
0.90
|
| Change In Other Current Liabilities |
|
-0.05
-145.71%
|
0.10
+284.21%
|
-0.06
-32.56%
|
-0.04
|
| Investing Cash Flow |
|
-0.00
|
0.00
+100.00%
|
-0.01
-166.67%
|
-0.00
|
| Cash Flow From Continuing Investing Activities |
|
-0.00
|
0.00
+100.00%
|
-0.01
-166.67%
|
-0.00
|
| Net PPE Purchase And Sale |
|
-0.00
|
0.00
+100.00%
|
-0.01
-166.67%
|
-0.00
|
| Purchase Of PPE |
|
-0.00
|
0.00
+100.00%
|
-0.01
-166.67%
|
-0.00
|
| Capital Expenditure |
|
-0.00
|
—
|
-0.01
-166.67%
|
-0.00
|
| Financing Cash Flow |
|
13.39
+13.18%
|
11.83
+9.58%
|
10.80
+972.19%
|
1.01
|
| Cash Flow From Continuing Financing Activities |
|
13.39
+13.18%
|
11.83
+9.58%
|
10.80
+972.19%
|
1.01
|
| Net Issuance Payments Of Debt |
|
—
|
0.00
-100.00%
|
1.25
+0.00%
|
1.25
|
| Issuance Of Debt |
|
—
|
0.00
-100.00%
|
1.25
-16.67%
|
1.50
|
| Repayment Of Debt |
|
—
|
—
|
0.00
+100.00%
|
-0.25
|
| Long Term Debt Issuance |
|
—
|
—
|
—
|
1.38
|
| Long Term Debt Payments |
|
—
|
—
|
—
|
-0.12
|
| Net Long Term Debt Issuance |
|
—
|
—
|
—
|
1.25
|
| Short Term Debt Issuance |
|
—
|
0.00
-100.00%
|
1.25
-16.67%
|
1.50
|
| Short Term Debt Payments |
|
—
|
—
|
0.00
+100.00%
|
-0.25
|
| Net Short Term Debt Issuance |
|
—
|
0.00
-100.00%
|
1.25
+0.00%
|
1.25
|
| Net Common Stock Issuance |
|
15.56
+18.75%
|
13.10
+6.96%
|
12.25
+9979.03%
|
-0.12
|
| Common Stock Payments |
|
-0.00
+0.00%
|
-0.00
|
0.00
+100.00%
|
-0.12
|
| Repurchase Of Capital Stock |
|
-0.00
+0.00%
|
-0.00
|
0.00
+100.00%
|
-0.12
|
| Proceeds From Stock Option Exercised |
|
0.00
-100.00%
|
0.76
+6250.00%
|
0.01
|
0.00
|
| Net Other Financing Charges |
|
-2.17
-6.69%
|
-2.03
+25.12%
|
-2.71
-2181.51%
|
-0.12
|
| Changes In Cash |
|
3.20
-0.59%
|
3.22
+78.99%
|
1.80
+2320.99%
|
-0.08
|
| Beginning Cash Position |
|
5.03
+178.10%
|
1.81
+19988.89%
|
0.01
-90.00%
|
0.09
|
| End Cash Position |
|
8.23
+63.66%
|
5.03
+178.10%
|
1.81
+19988.89%
|
0.01
|
| Free Cash Flow |
|
-10.19
-18.33%
|
-8.61
+4.30%
|
-9.00
-727.02%
|
-1.09
|
| Interest Paid Supplemental Data |
|
—
|
—
|
0.00
-100.00%
|
0.03
|
| Common Stock Issuance |
|
15.56
+18.75%
|
13.10
+6.96%
|
12.25
|
0.00
|
| Issuance Of Capital Stock |
|
15.56
+18.75%
|
13.10
+6.96%
|
12.25
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-02-04 View
- 10-K2026-01-30 View
- 8-K2026-01-30 View
- 8-K2026-01-28 View
- 8-K2026-01-21 View
- 8-K2026-01-16 View
- 8-K2026-01-15 View
- 8-K2026-01-09 View
- 8-K2026-01-08 View
- 8-K2025-12-12 View
- 8-K2025-12-12 View
- 8-K2025-12-10 View
- 8-K2025-12-08 View
- 8-K2025-12-02 View
- 10-Q2025-11-14 View
- 42025-09-22 View
- 42025-09-22 View
- 42025-09-22 View
- 42025-09-22 View
- 42025-09-22 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|